Cancer Gene Therapy Market Share Analysis Report, 2024-2033
The global cancer gene therapy market size was exhibited at USD 2.95 billion in 2023 and is projected to hit around USD 18.11 billion by 2033, growing at a CAGR of 19.9% during the forecast period 2024 to 2033.
Key Takeaways:
The U.S. cancer gene therapy market size was valued at USD 1.25 billion in 2023 and is anticipated to reach around USD 7.94 billion by 2033, growing at a CAGR of 20.31% from 2024 to 2033.
North America accounted for the largest share of over 61.15% in 2023. This is attributed to the conducive environment facilitated by the government and the National Cancer Institute that supports research and development activities to enhance cancer therapeutics. Further, the presence of key market players in the region, their research efforts in devising gene therapy for cancer treatment, and collaborative efforts among market players to enhance research are boosting the market growth in the region. For instance, in August 2022, Merck & Co., Inc., collaborated with Orna Therapeutics Inc., for discovery, development, and commercialization of multiple programs, inclusive of utilization of mRNA for cancer gene therapy.
Europe is estimated to be the fastest-growing region over the forecast period due to increase in research funding for novel therapeutics by government bodies and increasing demand for novel therapeutics that could help combat the growing incidence of cancer cases across the region. Moreover, The European Union’s ‘Horizon Europe Mission on Cancer’ was launched in September 2023 so as to offer funds to a broad spectrum of activities that are intended to lower Europe’s cancer burden by accelerating research and innovation in cancer therapeutics. The mission is anticipated to help over 3 million cancer survivors by the year 2033.
The cancer gene therapy market in the Asia Pacific (APAC) region is segmented into India, China, Japan, South Korea, and the rest of the Asia Pacific (APAC) region. China dominated the Asia Pacific region followed by Japan and India in 2023.
The Latin America, Middle East, and African (LAMEA) cancer gene therapy market is segmented into North Africa, South Africa, Saudi Arabia, Brazil, Argentina, and the Rest of LAMEA. The Middle East and the Latin America region are anticipated to have notable growth in the cancer gene therapy market during the forecast period. Brazil held the largest share in the LAMEA region in 2023. Due to low literacy, uncertainty, and civil war in African countries, the cancer gene therapy market in Africa is expected to grow at a comparatively slow rate.
Cancer Gene Therapy Marke Report Scope
| Report Coverage | Details |
| Market Size in 2024 | USD 3.54 Billion |
| Market Size by 2033 | USD 18.11 Billion |
| Growth Rate From 2024 to 2033 | CAGR of 19.9% |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Segments Covered | Therapy, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | Abeona Therapeutics Inc.; Asklepios BioPharmaceutical Inc.; Altor Bioscience Inc.; Bluebird bio Inc.; BioCancell Inc.; Celgene Inc.; Elevate Bio Inc.; GlaxoSmithKline Inc.; Genelux Corporation; GenVec; Introgen Therapeutics Inc.; Merck KGaA; OncoGenex Pharmaceuticals Inc. |
The growth of the market is attributed to factors such as the growing demand for gene therapy and an increased incidence of cancer cases across the globe. Moreover, with the emergence of advancements in gene therapy, it is anticipated to become an effective alternative exercise for the treatment of all types of cancers and neoplastic disorders. For instance, in March 2023, the U.S. FDA approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to be used for the treatment of patients with multiple myeloma who were incapable to respond to the initial lines of therapy.
The COVID-19 pandemic outbreak had posed challenges to the continuance of cell and gene therapy research exercises in terms of mobilization of resources and manufacturing capacities. Nevertheless, some cancer gene therapies have made it to secure regenerative medicine advanced therapy (RMAT) and priority medicine (PRIME) designation. For instance, in October 2020, Orca-T (by Orca Bio) was granted RMAT to be used for subjects with blood cancers. Similarly, ADP-A2M4, transduced CD4+ and CD8+ cells (by Adaptimmune) were granted PRIME to be used for the treatment of HLA-A positive subjects with metastatic synovial sarcoma.
The increasing prevalence of cancer cases is expected to create a high demand for novel therapeutic drugs that could be effective for cancer treatment. The emerging role of immunotherapy in cancer treatment has rendered the focus of conventional gene therapies to target the immune system to yield better remissions for subjects with cancers at an advanced stage. For instance, in September 2022, the Hadassah Cancer Research Institute (HCRI), Jerusalem declared that it will lead the CancerRNA, a global forum working towards development and application of RNA-based immunotherapy to effectively utilize anti-cancer immune responses.
Furthermore, the growth of the market is attributed to the extensive research and development strategies carried out by biopharmaceutical companies for the production of novel therapeutic drugs. Leading market players are focusing on R&D and regional expansion strategies for better market penetration. For instance, in August 2022, Bluebird bio's BLUE.O gene therapy secured FDA approval for use in the treatment of subjects with a rare disorder requiring a regular blood transfusion process. The drug is priced at USD 2.8 million per unit.
The market players are extensively working towards collaborations, expansions, acquisitions, and huge capital investments to advance research in gene therapy to yield novel therapeutic drugs for the treatment of different types of cancers. For instance, in April 2022, GlaxoSmithKline plc declared the acquisition of Sierra Oncology to advance the therapeutic research on rare forms of cancer for USD55 per share featuring a total equity value of USD 1.9 billion.
Therapy Insights
Gene induced immunotherapy dominated the market with a revenue share of over 41.9% in 2023. The dominance of the segment can be attributed to research studies aiming to lower the proliferation of various types of cancer by strengthening the immune system. Many gene therapies for cancers are designed on the basis of immunotherapy elements. For instance, PROVENGE (by Dendreon Corporation) is an autologous cellular immunotherapy designed to stimulate a subject’s immune system against prostate cancer.
Oncolytic virotherapy is expected to grow at the fastest rate over the forecast period owing to the favorable outcomes and the level of efficacy offered by oncolytic virotherapy. Oncolytic viruses can combat cancer cells without disturbing the healthy cells in vicinity by stimulating natural killer cells. Moreover, there are lucrative research grants for the research on oncolytic virotherapy. For instance, in July 2022, the researchers at the Center for Nuclear Receptors and Cell Signaling at the University of Houston received a USD 1.8 million grant from the National Institutes of Health to work on oncolytic virotherapy.
End-use Insights
Biopharmaceutical companies led the market with a revenue share of over 50.0% in 2023. This is attributed to the increasing global prevalence of different types of cancers owing to various hereditary, environmental, and lifestyle risk factors. Moreover, the market is driven by increasing adoption of elemental gene therapy options by biopharmaceutical giants to design cancer therapeutic regimes. Many novel therapeutic drugs are under different phases of trials and firms are striving to market them in different regions across the globe. For instance, in January 2020, bluebird bio, Inc. launches its drug, ZYNTEGLO in Germany to be used as a one-time gene therapy solution for patients aged 12 years and above.
The biopharmaceutical companies segment is projected to grow at the fastest rate over the forecast period. The increasing global prevalence of malignant tumors is a key factor driving the market. Moreover, an increased interest in oncology therapeutics research and development is resulting in a rise in the number of FDA approvals of gene therapy drugs. For instance, there are 6 FDA-approved cancer gene therapy drugs with Tecratus, Abcema, and Kymriah being the recent approvals.
Recent Developments:
Some of the prominent players in the Cancer gene therapy market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2023 to 2033. For this study, Nova one advisor, Inc. has segmented the global cancer gene therapy market.
Therapy
End-use
By Region
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers